compound 39 [PMID: 31742400]   Click here for help

GtoPdb Ligand ID: 10585

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Compound 39 is a dual antagonist of the CC-chemokine receptors CCR2 and CCR5 [3]. It is one of the most potent lead molecules that were reported in this 2019 Journal of Medicinal Chemistry paper. Experiments measuring antagonism of CCL3-induced [35S]GTPγS binding indicates that 39 binds to an allosteric site of both target receptors, which is likely to be located on the intracellular face of the receptiors. The compound is described as an insurmountable antagonist.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 89.07
Molecular weight 351.07
XLogP 3.79
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Nc1nn2c(n1)[nH]c(c(c2=O)Cc1cccc(c1Cl)Cl)C(C)C
Isomeric SMILES Nc1nn2c(n1)[nH]c(c(c2=O)Cc1cccc(c1Cl)Cl)C(C)C
InChI InChI=1S/C15H15Cl2N5O/c1-7(2)12-9(6-8-4-3-5-10(16)11(8)17)13(23)22-15(19-12)20-14(18)21-22/h3-5,7H,6H2,1-2H3,(H3,18,19,20,21)
Immunopharmacology Comments
Dual CCR2/CCR5 antagonism is being examined as a strategy to deliver enhanced therapeutic efficacy in inflammatory diseases where both receptors are involved [1,4]. Cenicriviroc was the first such dual antagonist to reach clinical evaluation [2].